Ann: CEO Presentation to 2023 Annual General Meeting, page-5

partnership strategy is hold some indications and partner on others. specifically the bigger more costly programs. keeping the smaller and or rarer to themselves.
silviu couldnt say whether it would be next week or next month but retiterated the negotiations are very advanced mentioning both back and heart.

so given the backpain pathway is already very clear and potential partners would know what lies in front of them, there should be no reason to delay a partnership unless they are holding off signing on for as long as possible, ideally keeping it for themselves but willing to partner as a backup plan.. maybe this is what makes slviu confident of being funded.
they could simply be waiting till after the pathway is clear for a potential partner with heart. thats the indicaton they have always said they would prefer to partner. but why havent they met with fda sooner?
could it be they were waiting on boston children data to add weight to the discussion?